They are primarily used in treating heart failure, particularly HFrEF, and have shown benefits in reducing morbidity and mortality when used alongside standard therapies like angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) [10,11,12]. Here, ACE is linked to heart failure.